Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several claims are unsupported or not assessable from the provided label excerpts (notably patent/generic/indication-primary-mechanism/general efficacy statements). Some safety statements (dizziness/somnolence) are supported, but overall alignment is poor because multiple items are outside label support or inaccurate relative to label scope.
Category Scores
Accurate Statements
Off-label use of Lyrica can increase the risk of adverse effects including dizziness.
Label includes: Warnings and Precautions (5.5) that LYRICA may cause dizziness and somnolence, with dizziness generally beginning after initiation and occurring more frequently at higher doses. (No off-label-specific language in provided excerpts.)
Off-label use of Lyrica can increase the risk of adverse effects including drowsiness.
Label includes: Warnings and Precautions (5.5) that LYRICA may cause dizziness and somnolence.
Unsupported Statements
There is no established recommended dosage of Lyrica (pregabalin) for endurance training.
The provided label excerpts do not address endurance training or any recommended dosing for that condition.
The typical dosage range for fibromyalgia and neuropathic pain with Lyrica is 150–600 mg per day, taken in divided doses.
The label excerpts provide: fibromyalgia 300–450 mg/day (with titration starting at 150 mg/day) and neuropathic pain associated with spinal cord injury 150–600 mg/day; the combined 'fibromyalgia and neuropathic pain' generalization and the specific 'typical range 150–600 mg/day' across both is not directly supported.
Using Lyrica for endurance training is off-label use.
The label excerpts show approved indications but do not explicitly state off-label use definitions for endurance training.
Lyrica is not approved by the FDA for endurance training.
The provided label excerpts list approved indications but do not explicitly mention 'endurance training.' This claim is not directly supported by the excerpts as written.
Off-label use of Lyrica can increase the risk of adverse effects including impaired cognitive function.
The provided excerpts for cognitive impairment are not included; only additive effects on cognitive and gross motor functioning with oxycodone/lorazepam/ethanol are mentioned, but not cognitive adverse effects due to off-label use.
The patent for Lyrica (pregabalin) expired in 2018.
Patent expiration date is not addressed in the provided label excerpts.
Generic versions of Lyrica entered the market due to patent expiration.
Market entry timing and causality are not addressed in the provided label excerpts.
Lyrica is primarily used to treat epilepsy.
The label indicates multiple uses (neuropathic pain, fibromyalgia, and adjunctive partial-onset seizures), but 'primarily used' is not supported by the provided label excerpts.
Lyrica is primarily used to treat fibromyalgia.
The label lists fibromyalgia as an indication, but 'primarily used' is not supported by the provided label excerpts.
Lyrica is primarily used to treat neuropathic pain.
The label lists several neuropathic pain indications, but 'primarily used' is not supported by the provided label excerpts.
Lyrica works by binding to specific receptors in the brain.
Supported mechanism excerpt states: binds with high affinity to the alpha2-delta site in central nervous system tissues; however, the claim is too general ('specific receptors in the brain') and not directly quoted as such in the provided excerpt.
Lyrica can reduce the frequency and severity of seizures.
The label excerpt states it is adjunctive therapy for partial-onset seizures, but the specific claim about 'reduce frequency and severity' is not stated in the provided excerpts.
Lyrica can alleviate pain.
The label supports indications for management of neuropathic pain and fibromyalgia, but the broad statement 'alleviate pain' is not directly stated as such in the provided excerpts.
Lyrica can improve sleep quality.
Sleep quality improvement is not addressed in the provided label excerpts.
Contradictions
Important Omissions
If discussing safety, the label emphasizes specific labeled effects/precautions (e.g., respiratory depression especially with CNS depressants/opioids; suicidal behavior/ideation monitoring; edema/weight gain).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Safety-related claims partially align (dizziness/somnolence). However, other safety assertions are unsupported (impaired cognitive function tied to off-label use), and multiple claims are unrelated to label-supported safety/dosing, which could mislead usage context.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Many claims are outside the provided label excerpts or are generalized (e.g., 'primarily used', 'improve sleep quality', patent/generic timing) and are not directly supported; one combined dosing range is also not accurately mapped to label-specific indications.
Suggested Improvement
Limit statements to label-supported indications and labeled dosing ranges by specific indication (e.g., fibromyalgia 300–450 mg/day; spinal cord injury neuropathic pain 150–600 mg/day). For safety, cite specific labeled warnings/precautions (e.g., dizziness/somnolence) and avoid attributing off-label-use risk increases or cognitive impairment unless explicitly supported in the provided excerpts. Remove patent/generic timing and 'primarily used' market-scope claims not present in the label.